**Core tip:** Cancer-derived exosomes carry a wide variety of DNA, RNA, proteins and lipids, which may serve as novel biomarkers in cancer. The current systematic review and meta-analysis summarized the performance of exosomal biomarkers in cancer diagnosis and prognosis. We analyzed 47 diagnostic markers and 50 prognostic markers from 56 studies with various type of cancer. We found that exosomal biomarkers had both diagnostic and prognostic power in many cancers.

INTRODUCTION
============

Cancer is the uncontrolled growth of cells and eventually leads to death. Cancer is the second cause of death, contributing to more than 8.8 million deaths every year\[[@B1],[@B2]\]. Among various types of cancer, lung cancer, gastrointestinal cancers (GI cancer), including liver cancer, pancreatic cancer and colorectal cancer, and breast cancer are the most common cause of cancer-related death\[[@B2]-[@B4]\]. Although chemotherapy, targeted therapy, surgical recession and radiotherapy can effectively prolong survival of patients, the survival rate of cancer is still very low, especially in GI cancer, being less than 20%\[[@B2]\]. One of the major reasons is the late diagnosis of cancer, in which patients are already with advanced and metastatic tumors. As a result, no therapies can effectively kill the cancer cells. The situation is even worse in pancreatic cancers at distant stage, with 5-year survival rate of only 3%\[[@B2]\].

Since more than half of the patients present with locally advanced or metastatic stage, early diagnosis and early treatment are fundamentally important for better prognosis. Therefore, many tumor makers have been developed, aiming at accurately detecting various types of cancer and monitoring the disease progression. Blood test of the tumor antigens carcinoembryonic antigen, carbohydrate antigen 19-9, and carbohydrate antigen 125 (known as CEA, CA19-9 and CA125 respectively) are commonly used for detection of many cancers, such as GI cancers, ovarian cancer and breast cancer\[[@B5]-[@B8]\]. However, the sensitivity of these cancer biomarkers is unsatisfactory\[[@B9]-[@B12]\]. Also, the fecal occult blood test of colorectal cancer and the invasion endoscopic detection of gastric and colon cancer represent a great inconvenience to the patients. Therefore, highly sensitive and non-invasive diagnostic markers are urgently needed for early detection of cancer.

Exosomes are microvesicles of 30-100 nm diameter, which are secreted by both normal cells and cancer cells. They are distributed in many body fluids such as blood, saliva and urine, and carry various types of biomolecules, including RNA, proteins and lipids, for inter-cellular communication\[[@B13]-[@B15]\]. During cancer development, cancer cells secrete more exosomes, with significant changes in composition\[[@B16]-[@B18]\]. These facilitate communication within the tumor environment, acquisition of drug resistance, and metastasis to distant organs\[[@B19]-[@B21]\]. Although many potential non-invasive biomarkers have been developed using liquid biopsy, such as serum and urine, studies have found that these biomarkers are commonly located in the exosomes\[[@B22],[@B23]\]. Enriching these exosomal biomarkers could achieve a higher diagnostic and prognostic efficiency\[[@B24]-[@B26]\]. Thus, exosomal biomarkers can be novel targets in cancer diagnosis and prognosis.

The objective of this systemic review and meta-analysis is to evaluate the diagnostic and prognostic potential of exosomes in patients with various types of cancer, based on current available data. This information will help in the development of novel non-invasive biomarkers for sensitive and specific diagnosis and prognosis of cancer.

MATERIALS AND METHODS
=====================

Search strategy
---------------

Electronic literature search was performed using the PubMed database, without any language restriction. Articles related to exosomes in cancer from 2010 to September 11, 2018 were identified using the following key words: "exosome" and "cancer" and ""diagnosis" or "prognosis"".

Inclusion and exclusion criteria
--------------------------------

Articles were reviewed by their titles, key words, abstracts and full text to identify eligible studies. Eligible studies were included based on the following inclusion criteria: (1) The original article was related to exosomal diagnostic or prognostic markers in cancer; (2) At least 10 patients and 10 matched controls were enrolled in the study; (3) For diagnostic markers, enough information, such as specificity and sensitivity, was provided to construct 2 × 2 table \[true positive (TP), true negative (TN), false positive (FP), false negative (FN)\]; and (4) For prognostic markers, enough information was provided to estimate the hazard ratios (HRs) and confidence intervals (CIs). The exclusion criteria were as follows: (1) Duplicate articles; (2) Review articles, abstracts, comments, letters, case-report; (3) Fundamental research or animal study; (4) Diagnostic or prognostic marker that was not specific to exosome; (5) Sample size was less than 10; (6) Performance of the biomarker was not statistically significant; or (7) Incomplete information to estimate diagnostic or prognostic accuracy.

Data extraction
---------------

Two reviewers (Chi-Hin Wong and Yang-Chao Chen) independently reviewed and extracted the data from the eligible studies according to the listed criteria. Any disagreement was resolved by consensus among the authors. The following data from included studies were extracted: first author's name, year of publication, sample size, cancer type, country of origin, source of exosome, isolation method of exosome, and detection method of biomarkers. For diagnostic studies, data for the cut-off value of tested targets, sensitivity, specificity, and area under the receiver operating characteristics curve (ROC) were also extracted. For prognostic studies, data for survival analysis, cut-off value, multivariable HR and its 95%CI were extracted. If odds ratio (OR) was reported, OR was converted to relative risk using the formula introduced by Zhang and Yu\[[@B27]\]. If either OR or HR was not reported, the method introduced by Tierney et al\[[@B28]\] was used to estimate the HR and its 95%CI from a Kaplan-Meier plot.

Quality assessment
------------------

For diagnostic studies, the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) was used to assess the quality of studies for the meta-analysis\[[@B29]\]. Briefly, 14 questions covering the patient selection, patient flow, index test and reference standard test were applied to each study and an answer of "Yes", "No" or "Unclear" was given to each study. Only answers of "Yes" were given a score.

For prognostic study, the quality of studies was assessed according to reporting recommendations for tumor marker prognostic studies (REMARK)\[[@B30]\]. Briefly, a checklist of 20 items was generated, covering patients' characteristics, samples' source and storage, assay methods, statistical analysis, and data interpretation. A score was given when the study fulfilled the requirement of each item.

Statistical analysis
--------------------

The statistical analysis of the diagnostic performance of biomarkers was performed using Meta-DiSc 1.4\[[@B31]\]. The 2 × 2 table of each study was used to assess the pooled sensitivity, specificity, positive likelihood ratio (PLR) and negative likelihood ratio (NLR). Also, the summary receiver operating characteristic (SROC) curve was plotted; the area under the curve (AUC) was calculated and Q\* index was estimated to assess the overall performance in cancer diagnosis. An AUC of 0.5 suggested no diagnostic ability; 0.7-0.8 suggested acceptable diagnostic performance; 0.8-0.9 was considered excellent, and 0.9-1.0 suggested outstanding performance\[[@B32]\]. Q\* was defined at a point in which sensitivity and specificity are equal. For statistical analysis of the prognostic performance of biomarkers, forest plots were constructed using the HR and its 95%CI of each biomarker to assess the overall prognostic performance of biomarkers on overall survival (OS), disease-free survival (DFS) and recurrence-free survival (RFS). Graphpad Prism 6 was used in constructing the forest plots. To elevate the heterogeneity between studies, Cochran-Q test and inconsistency index (*I*^2^) statistics were calculated\[[@B33],[@B34]\]. *P*-value of \< 0.05 for Cochran-*Q* test or *I*^2^ \>50% suggested the presence of heterogeneity.

RESULTS
=======

Literature search
-----------------

Initially, 1233 articles were identified based on the search strategies. Based on title and abstract screening, 705 were not related to exosome biomarkers in cancer diagnosis or prognosis, and 287 were review articles. Upon further full-text review, 56 studies were basic studies, 42 studies with sample size less than 10 in either group (test group or control group), 12 studies analyzed the performance of combined markers, 70 studies did not provide enough information for analysis, and 5 studies were without statistical significance. Finally, 56 eligible studies were included for systematic review (Figure [1](#F1){ref-type="fig"}). Of these, 22 candidate studies were related to diagnosis, 34 candidate studies were related to prognosis, and 8 studies were related to both diagnosis and prognosis.

![Literature search process to select studies which evaluated the diagnostic or prognostic performance of exosomal biomarkers in cancer.](WJCC-7-171-g001){#F1}

Assessment of study quality
---------------------------

For diagnostic studies, the QUADAS-2 system was used to assess the study quality (Figure [2A](#F2){ref-type="fig"}). Most of the studies on diagnosis were with moderate-to-high quality, revealed by low risk of publication bias. However, there may be risk of bias in "patient selection" and "flow and timing". This may due to control-based design in most of the studies. Also, time between the index test and the reference test is poorly reported. Importantly, many studies did not provide enough information on how the patients were selected and classified. Patients excluded from the 2 × 2 table were often observed in some studies.

![Quality assessment of the studies in this meta-analysis. A: QUADAS-2 system was used to assess the quality of diagnostic studies; B: REMARK checklist was used to assess the quality of prognostic studies.](WJCC-7-171-g002){#F2}

The REMARK system was used to assess the quality of prognostic studies (Figure [2B](#F2){ref-type="fig"}). Most of the studies ( \> 90%) clearly stated the objective, biomarkers examined, source of exosomes, and methodology of isolation and detection. Also, most of the studies clearly defined the clinical endpoints and the period of the follow-up time. However, details in patient's characteristics during the follow-up period, such as the use of post-operative adjuvant therapy which significantly affects the OS and DFS, were lacking in most of the studies. Importantly, some studies did not clearly report the clinicpathological characteristics of the patients enrolled. Also, some studies did not show the relationship of the tested biomarkers to prognostic variables, including tumor stages and tumor differentiation. Twelve prognostic marker studies did not perform univariable or multivariable analysis. Twenty-eight of the enrolled studies reported multivariable analysis in prognostic markers, but only five studies clearly stated the adjustment factors.

Diagnostic markers
------------------

Diagnostic markers from 30 studies were included in the meta-analysis (Table [1](#T1){ref-type="table"}). More than a half of these studies were related to GI cancers (4 studies were about colon cancer; 5 studies were related to liver cancer; 4 studies were about pancreatic or pancreatobiliary tract cancer; and 4 studies were related to gastric cancer). A total of 2240 patients were included in the meta-analysis, with 12 studies having enrolled \< 50 patients, 16 studies having enrolled 50-100 patients, and 6 studies having enrolled \> 100 patients. There were 47 diagnostic biomarkers analyzed in the meta-analysis. There were 42.6% of the biomarkers as miRNAs, followed by lncRNAs (36.2%) and proteins (19.1%). Notably, 6 studies analyzed the diagnostic performance of exosomal miR-21 in various types of cancer. Also, 61.3%, 16.1%, 12.9%, 3.2% and 3.2% of the biomarkers were detected in serum, plasma, urine, saliva and bile respectively.

###### 

Studies included for meta-analysis of exosomal biomarkers in cancer diagnosis

  ------------------------------ ------------- -------------------------------- ----------- ---------------------------------------- ----------------------- ------------------------ ------------ --------------------------------- ------------------- ---------------------- ----------------------------------------------------------------- -------- -------- -------- --------
  **Ref.**                       **Country**   **Cancer type**                  **Stage**   **Control**                              **Number of Control**   **Number of patients**   **Sample**   **Isolation method of exosome**   **Marker**          **Detection method**   **Cut-off**                                                       **TP**   **TN**   **FP**   **FN**
  Sun et al\[[@B35]\]            China         Colorectal                       All         Healthy                                  32                      92                       Plasma       UC                                CPNE3               ELISA                  0.143 pg/μg exosome                                               62       27       5        30
  Ogata-Kawata et al\[[@B36]\]   Japan         Colorectal                       All         Healthy                                  11                      88                       Serum        UC                                miR-1246            qRT-PCR                1.45                                                              84       10       4        1
  miR-23a                        0.3100        81                               11          7                                        0                                                                                                                                                                                                                                       
  miR-21                         1.08          54                               10          34                                       1                                                                                                                                                                                                                                       
  miR-150                        0.08          49                               11          39                                       0                                                                                                                                                                                                                                       
  let-7a                         0.9           44                               10          44                                       1                                                                                                                                                                                                                                       
  miR-223                        1.72          41                               10          47                                       1                                                                                                                                                                                                                                       
  miR-1224-5p                    0.5           28                               11          60                                       0                                                                                                                                                                                                                                       
  miR-1229                       0.06          20                               11          68                                       0                                                                                                                                                                                                                                       
  Liu et al\[[@B37]\]            China         Colorectal                       All         Healthy and benign                       320                     148                      Serum        ExoQuick                          CRNDE-h             qRT-PCR                0.02                                                              104      302      18       44
  Uratani et al\[[@B38]\]        Japan         Colorectal                       NR          Healthy                                  47                      26                       Serum        ExoQuick                          miR-21              qRT-PCR                Youden index                                                      18       38       9        8
  Lin et al\[[@B39]\]            China         Gastric                          All         Healthy                                  60                      51                       Plasma       UC                                lncUEGC1            qRT-PCR                NR                                                                45       50       10       6
                                                                                            lncUEGC2                                 NR                      46                       34           26                                17                                                                                                                                      
  Zhao et al\[[@B40]\]           China         Gastric                          All         Healthy                                  120                     126                      Serum        NR                                HOTTIP              qRT-PCR                1.72                                                              88       102      18       38
  Pang et al\[[@B41]\]           China         Gastric                          All         Healthy                                  37                      40                       Serum        ExoQuick                          ZFAS1               qRT-PCR                NR                                                                32       28       9        8
  Yang et al\[[@B42]\]           China         Gastric                          All         Healthy                                  80                      80                       Serum        ExoQuick                          miR-423-5p          qRT-PCR                NR                                                                65       46       34       15
  Goto et al\[[@B43]\]           Japan         Pancreatic                       All         Healthy and advanced pancreatic cancer   22                      23                       Serum        ExoQuick                          miR-191             qRT-PCR                Distance = (1-sensitivity)^2^ + (1-specificity)^2^ in ROC curve   18       17       5        5
  miR-21                         20            18                               4           3                                                                                                                                                                                                                                                                                
  miR-451a                       16            18                               4           7                                                                                                                                                                                                                                                                                
  Melo et al\[[@B44]\]           Germany       Pancreatic                       All         Healthy                                  100                     190                      Serum        UC                                GPC1                Flow cytometry         Youden index                                                      190      100      0        0
  Que et al\[[@B45]\]            China         Pancreatic                       All         Non-PDAC                                 27                      22                       Serum        UC                                miR-17-5p           qRT-PCR                6.826                                                             20       20       7        2
  miR-21                         7.693         18                               26          1                                        4                                                                                                                                                                                                                                       
  Machida et al\[[@B46]\]        Japan         Pancreatobiliary tract           II-IV       Healthy                                  13                      12                       Saliva       Total exosome isolation kit       miR-1246            qRT-PCR                13.77                                                             8        13       0        4
  miR-4644                       -5.205        9                                10          3                                        3                                                                                                                                                                                                                                       
  Xu et al\[[@B47]\]             China         Liver                            All         Chronic hepatitis B                      68                      88                       Serum        Total exosome isolation kit       hnRNPH1             qRT-PCR                0.67                                                              75       52       16       13
  Sun et al\[[@B48]\]            China         Liver                            All         Healthy                                  56                      56                       Serum        Total exosome isolation kit       LINC00161           qRT-PCR                NR                                                                42       41       15       14
  Xu et al\[[@B49]\]             China         Liver                            All         Chronic hepatitis B                      96                      60                       Serum        Total exosome isolation kit       ENSG00000258332.1   qRT-PCR                1.345                                                             43       80       16       17
  60                             55            ENSG00000258332.1                1.366       40                                       48                      12                       15                                                                                                                                                                                     
  96                             60            LINC00635                        1.69        46                                       75                      21                       14                                                                                                                                                                                     
  60                             55            LINC00635                        1.532       44                                       45                      15                       11                                                                                                                                                                                     
  Goldvaser et al\[[@B50]\]      Israel        Pan-cancer (not include liver)               Healthy                                  45                      98                       Serum        Total exosome isolation kit       hTERT               qRT-PCR                NR                                                                61       45       0        37
  Liver                          NR            Healthy                          45          35                                       NR                      21                       45           0                                 14                                                                                                                                      
  Zhang et al\[[@B51]\]          China         Lung                             All         Healthy                                  30                      77                       Serum        ExoQuick                          MALAT-1             qRT-PCR                NR                                                                62       21       9        15
  Sun et al\[[@B52]\]            China         Lung                             All         Healthy                                  15                      15                       Plasma       UC                                14-3-3ζ             ELISA                                                                                    9        12       3        6
  Li et al\[[@B53]\]             NR            Ovarian                                      Benign                                   21                      50                       Serum        UC                                ephrinA2            ELISA                  20.4 ng/L                                                         44       17       4        6
  Meng et al\[[@B54]\]           NR            Ovarian                          All         Benign                                   20                      163                      Serum        Total exosome isolation kit       miR-200a            PCR+ qRT-PCR           Youden index                                                      135      18       2        28
  miR-200b                       86            20                               0           77                                                                                                                                                                                                                                                                               
  miR-200c                       51            20                               0           112                                                                                                                                                                                                                                                                              
  Pan et al\[[@B55]\]            Germany       Ovarian                          All         Healthy                                  29                      106                      Plasma       ExoQuick                          miR-21              PCR+ qRT-PCR           Youden index                                                      65       24       5        41
  miR-100                        66            21                               8           40                                                                                                                                                                                                                                                                               
  miR-200b                       68            25                               4           38                                                                                                                                                                                                                                                                               
  miR-320                        59            20                               9           47                                                                                                                                                                                                                                                                               
  Bryzgunova et al\[[@B56]\]     Russia        Prostate                         All         Healthy                                  20                      14                       Urine        UC                                miR-125             qRT-PCR                NR                                                                12       13       7        2
  miR-19b                        NR            11                               19          1                                        3                                                                                                                                                                                                                                       
  Wang et al\[[@B57]\]           China         Prostate                         II-IV       Healthy                                  30                      34                       Plasma       Total exosome isolation kit       SAP30L-AS1          qRT-PCR                NR                                                                21       25       5        13
  SChLAP1                        NR            30                               23          7                                        4                                                                                                                                                                                                                                       
  Øverbye et al\[[@B58]\]        NR            Prostate                         All         Healthy                                  15                      16                       Urine        UC                                ADIRF               Mass spectrometry      Youden index                                                      12       16       0        3
  TMEM256                        14            16                               0           1                                                                                                                                                                                                                                                                                
  Işın et al\[[@B59]\]           NR            Prostate                         All         BPH                                      49                      30                       Urine        Urine Exosome RNA Isolation Kit   LincRNA-p21         qRT-PCR                0.181                                                             20       31       18       10
  Wang et al\[[@B60]\]           China         Laryngeal                        All         Vocal cord polyps                        49                      52                       Serum        ExoQuick                          miR-21              qRT-PCR                0.043                                                             36       40       9        16
  HOTAIR                                       0.032                            48          28                                       21                      4                                                                                                                                                                                                               
  Alegre et al\[[@B61]\]         NR            Melanoma                         NR          Healthy                                  25                      53                       Serum        ExoQuick                          exo-MIA             ELISA                  1.4 μg/L                                                          42       20       5        11
  exo-S100B                      ELISA         0.015 μg/L                       42          20                                       5                       11                                                                                                                                                                                                              
  Manterola et al\[[@B62]\]      France        GBM                              NR          Healthy                                  30                      50                       Serum        ExoQuick                          RNU6                qRT-PCR                0.372                                                             33       20       10       17
  Chen et al\[[@B63]\]           Taiwan        Bladder                          All         hernia                                   81                      140                      Urine        UC                                TACSTD2             ELISA                  2.47 ng/mL                                                        103      62       19       37
  Ge et al\[[@B64]\]             China         Cholangiocarcinoma               All         Biliary obstruction                      56                      35                       Bile         UC                                ENST00000588480.1   qRT-PCR                NR                                                                22       41       15       13
  ------------------------------ ------------- -------------------------------- ----------- ---------------------------------------- ----------------------- ------------------------ ------------ --------------------------------- ------------------- ---------------------- ----------------------------------------------------------------- -------- -------- -------- --------

UC: Ultracentrifugation; NR: Not reported.

Since a wide range of cancers was studied by different groups, we separated the diagnostic biomarkers according to cancer types and meta-analyzed cancer types with more than three biomarkers studied. Therefore, we focused on colorectal cancer (4 studies with 11 biomarkers), gastric cancer (4 studies with 5 biomarkers), pancreatic cancer (4 studies with 8 biomarkers), liver cancer (4 studies with 7 biomarkers), and prostate cancer (4 studies with 7 biomarkers (Figures [3](#F3){ref-type="fig"}-[7](#F7){ref-type="fig"}). We observed that the pooled biomarkers had a good specificity of 0.87 but poor sensitivity of 0.57 in colorectal cancer diagnosis (Figure [3A](#F3){ref-type="fig"} and B). The PLR and NLR were 2.02 and 0.21 respectively (Figure [3C](#F3){ref-type="fig"} and D). The diagnostic OR was 20.35 (Figure [3E](#F3){ref-type="fig"}). Importantly, the AUC of the SROC curve was 0.89 and the Q\* was 0.82 (Figure [3F](#F3){ref-type="fig"}). In diagnosis of gastric cancer, we observed that the pooled biomarkers had a good sensitivity of 0.77 and specificity of 0.73 with PLR, NLR, AUC of the SROC curve and Q\* of 2.94, 0.32, 9.88, 0.84 and 0.77 respectively (Figure [4](#F4){ref-type="fig"}). For diagnosis of pancreatic cancer, we also observed the pooled biomarkers had an excellent sensitivity of 0.91 and specificity of 0.90 with PLR, NLR, AUC of the SROC curve and Q\* of 6.35, 0.19, 40.71, 0.94 and 0.88 respectively (Figure [5](#F5){ref-type="fig"}). In liver cancer, the pooled biomarkers had a good diagnostic sensitivity of 0.76 and specificity of 0.80 with PLR, NLR, AUC of the SROC curve and Q\* of 3.51, 0.32, 12.45, 0.85 and 0.78 respectively (Figure [6](#F6){ref-type="fig"}). The pooled biomarkers also had a good sensitivity of 0.77 and specificity of 0.79 in detecting prostate cancer with PLR, NLR, AUC of the SROC curve and Q\* of 3.84, 0.28, 17.88, 0.88 and 0.80 respectively (Figure [7](#F7){ref-type="fig"}). The high sensitivity, specificity and Q\* demonstrated that the pooled biomarkers could effectively discriminate cancer patients from healthy people or non-cancer patients.

![Forest plot of pooled (A) sensitivity, (B) specificity, (C) positive likelihood ratio, (D) negative likelihood ratio, (E) diagnostic odds ratio and (F) SROC curve of exosomal biomarkers in diagnosis of colon cancer. SROC: Summary receiver operating characteristic.](WJCC-7-171-g003){#F3}

![Forest plot of pooled (A) sensitivity, (B) specificity, (C) positive likelihood ratio, (D) negative likelihood ratio, (E) diagnostic odds ratio, and (F) SROC curve of exosomal biomarkers in diagnosis of gastric cancer. SROC: Summary receiver operating characteristic.](WJCC-7-171-g004){#F4}

![Forest plot of pooled (A) sensitivity, (B) specificity, (C) positive likelihood ratio, (D) negative likelihood ratio, (E) diagnostic odds ratio and (F) SROC curve of exosomal biomarkers in diagnosis of pancreatic cancer. SROC: Summary receiver operating characteristic.](WJCC-7-171-g005){#F5}

![Forest plot of pooled (A) sensitivity, (B) specificity, (C) positive likelihood ratio, (D) negative likelihood ratio, (E) diagnostic odds ratio, and (F) SROC curve of exosomal biomarkers in diagnosis of liver cancers. SROC: Summary receiver operating characteristic.](WJCC-7-171-g006){#F6}

![Forest plot of pooled (A) sensitivity, (B) specificity, (C) positive likelihood ratio, (D) negative likelihood ratio, (E) diagnostic odds ratio, and (F) SROC curve of exosomal biomarkers in diagnosis of prostate cancers. SROC: Summary receiver operating characteristic.](WJCC-7-171-g007){#F7}

Prognostic markers
------------------

Prognostic biomarkers from 42 studies were included in the systematic review (Table [2](#T2){ref-type="table"}). In total, 4797 patients were represented among the studies, with 7 studies having enrolled \< 50 patients, 15 studies having enrolled 50-100 patients, and 20 studies having enrolled \> 100 patients. There were 50 prognostic biomarkers analyzed in the systematic review, with 60% of the biomarkers being miRNAs, followed by lncRNAs (18%) and proteins (16%). Also, 50%, 43%, 2.4%, 2.4% and 2.4% of the biomarkers were detected in serum, plasma, bile, ascetic fluid and cell-free effusion supernatant respectively. For the included studies, 92.9%, 26.2% and 9.5% used OS, DFS and RFS respectively as the primary endpoints. In addition, a wide range of cancers was studied by the different groups. More than one-half of the included studies were related to GI cancers (11 studies were about colorectal or colon cancer, 5 studies were related to liver cancer, 5 studies were about pancreatic cancer, and 4 studies were related to gastric cancer). In this meta-analysis, we separated studies according to clinical endpoints and focused on cancer types with more than three biomarkers studied.

###### 

Studies included for meta-analysis of exosomal biomarkers in cancer prognosis

  ---------------------------------- ------------------- ------------------ --------------------- --------------------------- ----------- ---------------------- --------------------------------- ----------------------- ------------------------- ----------------------- ----------------------- ------------------------
  **Ref.**                           **Period**          **Country**        **Sample** **Size**   **Cancer** **Type**         **Stage**   **Sample**             **Isolation method of exosome**   **Marker**              **Detection method**      **Cut-off value**       **Survival analysis**   **HR (95%CI)**
  Peng et al\[[@B65]\]               2008-2014           China              108                   Colorectal                  All         Serum                  Total exosome isolation kit       miR-548c-5p             qRT-PCR                   NR                      OS                      3.40 (1.02‐11.27)
  Sun et al\[[@B35]\]                2012-2017           China              92                    Colorectal                  All         Plasma                 UC                                CPNE3                   ELISA                     ≥ 0.143 pg/μg exosome   OS                      3.0 (1.0-8.9)
  ≥ 0.143 pg/μg exosome              DFS                 2.5 (1.1-5.5)                                                                                                                                                                                                                               
  Tsukamoto et al\[[@B66]\]          2002-2012           Japan              326                   Colorectal                  II-IV       Plasma                 UC                                miR-21                  qRT-PCR                   \> median               OS                      2.28 (1.81-5.74)
  DFS                                2.34 (1.87- 4.60)                                                                                                                                                                                                                                               
  Liu et al\[[@B37]\]                2007-2010           China              148                   Colorectal                  All         Serum                  ExoQuick                          CRNDE-h                 qRT-PCR                   \> 0.02                 OS                      2.000 (1.269-3.154)
  Liu et al\[[@B67]\]                2006-2011           United States      84                    Colorectal                  II-III      Serum                  ExoQuick                          miR-4772-3p             qRT-PCR                   ≥ 27.88                 OS                      6.19 (1.50-25.5)
  ≥ 27.88                            RFS                 5.48 (2.49-12.1)                                                                                                                                                                                                                            
  Liu et al\[[@B24]\]                2013-2014           China              158                   Colorectal                  All         Plasma                 UC                                lncRNA GAS5             qRT-PCR                   NR                      OS                      0.265 (0.082 -0.844)
                                                                            RFS                   0.449 (0.194- 0.909)                                                                                                                                                                               
  miR-221                            qRT-PCR             NR                 OS                    2.141 (1.368-3.054)                                                                                                                                                                                
                                                                            RFS                   1.600 (1.162-2.007)                                                                                                                                                                                
  Gao et al\[[@B68]\]                2011-2014           China              108                   Colorectal                  All         Serum                  ExoQuick                          91H                     qRT-PCR                   ≥ 0.85                  RFS                     7.14 (1.23-21.35)
  Yan et al\[[@B69]\]                NR                  NR                 168                   Colorectal                  All         Serum                  Total Exosome Isolation kit       miR-6803                qRT-PCR                   NR                      OS                      2.93 (1.35-6.37)
  DFS                                3.26 (1.56-6.81)                                                                                                                                                                                                                                                
  Li et al\[[@B70]\]                 2013-2015           China              85                    Colorectal                  III         Plasma                 ExoCapTM                          GPC1                    Flow cytometry            \> mean                 OS                      1.89 (1.23-2.89)
  Silva et al\[[@B71]\]              2003-2009           Spain              91                    Colorectal                  All         Plasma                 UC                                Exosome                 Flow cytometry of EpCAM   High                    OS                      0.87 (0.57-1.32)
  Matsumura et al\[[@B72]\]          1992-2007           Japan              209                   Colorectal                  All         Serum                  UC                                miR-19                  qRT-PCR                   \> mean                 O                       2.49 (1.12-6.61)
  DFS                                2.49 (1.12-6.61)                                                                                                                                                                                                                                                
  Yan et al\[[@B73]\]                2012-2015           China              142                   Colorectal                  All         Serum                  Total Exosome Isolation kit       miR-6869-5p             qRT-PCR                   \< mean                 OS                      2.32 (1.08-4.99)
  Santasusagna et al\[[@B25]\]       2009-2013           Spain              32                    Colon                       I-III       Plasma                 UC                                miR-141                 qRT-PCR                   High                    OS                      1.89 (0.93-3.83)
  Zhao et al\[[@B40]\]               2011-2012           China              126                   Gastric                     All         Serum                  NR                                HOTTIP                  qRT-PCR                   \> 1.72                 OS                      2.037 (1.085-3.823)
  Liu et al\[[@B74]\]                2012-2017           China              76                    Gastric                     All         Serum                  Total Exosome Isolation kit       miR-451                 qRT-PCR                   \> median               5yr-OS                  4.344 (2.853‐5.721)
  Yang et al\[[@B42]\]               NR                  China              80                    Gastric                     All         Serum                  ExoQuick                          miR-423-5p              qRT-PCR                   \> median               DFS                     1.93 (1.25-2.99)
  OS                                 1.42 (0.92-2.20)                                                                                                                                                                                                                                                
  Kumata et al\[[@B75]\]             2006-2013           Japan              232                   Gastric                     All         Plasma                 UC                                miR23b                  qRT-PCR                   \> 0.78                 OS                      0.57 (0.370.78)
  DFS                                0.64 (0.410.91)                                                                                                                                                                                                                                                 
  Zhou et al\[[@B76]\]               2010-2014           China              152                   Pancreatic                  All         Plasma                 ExoQuick                          miR-125b-5p             qRT-PCR                   \< median               OS                      0.285 (0.108-0.75)
  Li et al\[[@B77]\]                 2012-2016           China              87                    Pancreatic                  All         Plasma                 NR                                circPDE8A               qRT-PCR                   \> median               OS                      1.764 (1.064-2.925)
  Goto et al\[[@B43]\]               2013-2015           Japan              32                    Pancreatic                  All         Serum                  ExoQuick                          miR-21                  qRT-PCR                   \> median               OS                      4.071 (1.832-11.996)
  Takahasi et al\[[@B78]\]           2013-2017           Japan              50                    Pancreatic                  I-II        Plasma                 UC                                miR-451a                qRT-PCR                   \> 1.75                 OS                      3.20 (1.07-11.94)
  DFS                                2.87 (1.23-7.23)                                                                                                                                                                                                                                                
  Xu et al\[[@B49]\]                 2012-2016           China              60                    Liver                       All         Serum                  Total Exosome Isolation kit       ENSG00000258332.1       qRT-PCR                   \> 1.845                OS                      2.22 (1.34-3.68)
  LINC00635                          qRT-PCR             \> 2.100           OS                    1.46 (0.88-2.43)                                                                                                                                                                                   
  Shi et al\[[@B79]\]                2008-2011           China              126                   Liver                       All         Serum                  Total Exosome Isolation kit       miR-638                 qRT-PCR                   NR                      3yr-OS                  3.52 (1.37-6.02)
  5yr-OS                             2.80 (1.24-4.31)                                                                                                                                                                                                                                                
  Liu et al\[[@B26]\]                2012                China              128                   Liver                       All         Serum                  ExoQuick                          miR-125b                qRT-PCR                   \< median               RFS                     0.14 (0.07-0.29)
  OS                                 0.36 (0.18-0.74)                                                                                                                                                                                                                                                
  Xue et al\[[@B80]\]                2015-2017           China              85                    Liver                       All         Serum                  Total Exosome Isolation kit       miR-93                  qRT-PCR                   NR                      OS                      1.47 (0.96-2.25)
  Liu et al\[[@B81]\]                2008-2013           China              32                    Hepatoblastoma (children)   All         Serum                  ExoQuick                          miR-21                  qRT-PCR                   NR                      EFS                     1.434 (1.257-2.766)
  Matsumoto et al\[[@B82]\]          2011-2012           Japan              66                    Esophageal                  All         Plasma                 Total Exosome Isolation kit       exosome                 AChE activity             \< 600 x 108/mL         OS                      2.177 (1.085-3.605)
  Lu et al\[[@B83]\]                 2007-2015           China              110                   Nasopharyngeal              All         Plasma                 UC                                miR-9                   qRT-PCR                   NR                      OS                      1.5 (1.03-2.18)
  Ye et al\[[@B84]\]                 2011-2013           China              83                    Nasopharyngeal              II-IV       Serum                  UC                                protein concentration   BCA assay                 \> 11 μg/mL             DFS                     214.22 (139.27-329.49)
  Huang et al\[[@B85]\]              NR                  NR                 23                    Prostate                    All         Plasma                 ExoQuick                          miR-1290                qRT-PCR                   \> mean                 OS                      1.79(1.30-2.48)
  miR-375                            qRT-PCR             \> mean            OS                    2.69(1.52-4.77)                                                                                                                                                                                    
  Tang et al\[[@B86]\]               NR                  NR                 35                    Ovarian                     All         Ascitic fluid          UC                                E-cadherin              NR                        \> 10 μg/mL             OS                      1.82 (0.53-3.58)
  Vaksman et al\[[@B87]\]            1998-2003                              86                    Ovarian                     III-IV      Effusion supernatant   ExoQuick                          miR-21                  qRT-PCR                   \> median               OS                      1.70 (1.1-2.59)
  Kanaoka et al\[[@B88]\]            2012-2017           Japan              285                   Lung                        I-III       Plasma                 UC                                miR-451a                qRT-PCR                   \> 1.45                 OS                      6.06 (2.61-15.94)
  DFS                                2.55 (1.44-4.65)                                                                                                                                                                                                                                                
  Liu et al\[[@B89]\]                2012-2014           China              196                   Lung                        All         Plasma                 ExoQuick                          miR-23b-3p              qRT-PCR                   High                    OS                      2.42 (1.45-4.04)
  miR-21-5p                          qRT-PCR             OS                 2.12(1.28-3.49)                                                                                                                                                                                                          
  miR-10b-5p                         qRT-PCR             OS                 2.22 (1.18-4.16)                                                                                                                                                                                                         
  Liu et al\[[@B90]\]                2012-2014           China              208                   Lung                        All         Plasma                 ExoQuick                          Exosome                 AChE activity                                     OS                      1.72 (1.05-2.83)
  Sandfeld-Paulsen et al\[[@B91]\]   2011-2014           Denmark            276                   Lung                        All         Plasma                 /                                 CD171                   ELISA                     NR                      OS                      0.56 (0.41-0.79)
  Flotilin1                          ELISA               NR                 OS                    0.63 (0.46-0.86)                                                                                                                                                                                   
  HER3                               ELISA               NR                 OS                    0.63 (0.46-0.86)                                                                                                                                                                                   
  GRP78                              ELISA               NR                 OS                    0.69 (0.51-0.91)                                                                                                                                                                                   
  Manier et al\[[@B92]\]             2006-2008           France             156                   Multiple myeloma            All         Plasma                 ExoQuick                          let-7b                  qRT-PCR                   \< median               OS                      2.83 (1.07-7.50)
  let-7b                             qRT-PCR             \< median          DFS                   1.90 (1.22-2.94)                                                                                                                                                                                   
  let-7e                             qRT-PCR             \< median          DFS                   2.01 (1.30-3.11)                                                                                                                                                                                   
  miR-106a                           qRT-PCR             \< median          DFS                   2.34 (1.52-3.61)                                                                                                                                                                                   
  miR-106b                           qRT-PCR             \< median          DFS                   3.54 (2.21-5.68)                                                                                                                                                                                   
  miR-155                            qRT-PCR             \< median          OS                    2.41 (0.96-6.05)                                                                                                                                                                                   
  miR-155                            qRT-PCR             \< median          DFS                   1.76 (1.15-2.69)                                                                                                                                                                                   
  miR-16                             qRT-PCR             \< median          DFS                   2.21 (1.41-3.47)                                                                                                                                                                                   
  miR-17                             qRT-PCR             \< median          DFS                   2.29 (1.48-3.55)                                                                                                                                                                                   
  miR-18a                            qRT-PCR             \< median          DFS                   4.52 (1.57-12.98)                                                                                                                                                                                  
  miR-18a                            qRT-PCR             \< median          OS                    2.76 (1.79-4.26)                                                                                                                                                                                   
  miR-20a                            qRT-PCR             \< median          DFS                   2.31 (1.52-3.53)                                                                                                                                                                                   
  Alegre et al\[[@B61]\]             NR                  NR                 53                    Melanoma                    NR          Serum                  ExoQuick                          MIA                     ELISA                     2.5 μg/L                OS                      1.28 (0.65-2.51)
  Lan et al\[[@B93]\]                2011-2012           China              60                    Glioma                      All         Serum                  ExoQuick                          miR-301a                qRT-PCR                   \>median                OS                      4.4 (3.1-9.6)
  Ge et al\[[@B64]\]                 NR                  China              35                    Cholangiocarcinoma          All         Bile                   UC                                ENST00000588480.1       qRT-PCR                   \> median               OS                      2.40 (1.24-4.66)
  ENST00000517758.1                  qRT-PCR             OS                 1.55 (0.80-3.01)                                                                                                                                                                                                         
  Fujii et al\[[@B94]\]              2005-2014           Japan              108                   Renal cell                  I-III       Serum                  Total Exosome Isolation kit       miR-224                 qRT-PCR                   \> median               OS                      9.1 (1.8-166.1)
  ---------------------------------- ------------------- ------------------ --------------------- --------------------------- ----------- ---------------------- --------------------------------- ----------------------- ------------------------- ----------------------- ----------------------- ------------------------

UC: Ultracentrifugation; OS: Overall survival; DFS: Disease-free survival; RFS: Recurrence free survival; EFC: Event-free survival; NR: Not reported.

For 13 biomarkers with OS reported in colon cancer, the pooled HR was 1.833 with *I^2^* of 62.14% and *P* = 0.002 (Figure [8A](#F8){ref-type="fig"}). Also, for 5 biomarkers with DFS reported in colon cancer, the pooled HR was 3.035 with *I^2^* of 0.00% and *P* = 0.536 (Figure [8B](#F8){ref-type="fig"}). Furthermore, for 4 biomarkers with RFS reported in colon cancer, the pooled HR was 1.645 with *I^2^* of 89.61% and *P* = 0.000 (Figure [8C](#F8){ref-type="fig"}). Apart from colon cancer, for the 4 biomarkers with OS reported in gastric cancer, the pooled HR was 1.836 with *I^2^* of 96.71 and *P* = 0.000 (Figure [9](#F9){ref-type="fig"}). In addition, for the 4 biomarkers with OS reported in pancreatic cancer, the pooled HR was 1.537 with *I^2^* of 81.50 and *P* = 0.001 (Figure [10](#F10){ref-type="fig"}). For 5 biomarkers, the pooled HR was 1.828, *I^2^* of 84.48% and *P* = 0.000 for prognosing OS in liver cancer (Figure [11](#F11){ref-type="fig"}). Also, 9 biomarkers with the pooled HR of 0.895, *I^2^* of 89.50% and *P* = 0.000 were reported to function as prognostic biomarkers of OS in lung cancer (Figure [12](#F12){ref-type="fig"}). These results demonstrated that exosomes were associated with OS, DFS and RFS in various types of cancer.

![Forest plot evaluating the effect of exosomal markers on overall survival (A), disease-free survival (B), and (C) recurrence-free survival of patients with colon cancer.](WJCC-7-171-g008){#F8}

![Forest plot evaluating the effect of exosomal markers on overall survival of patients with gastric cancer.](WJCC-7-171-g009){#F9}

![Forest plot evaluating the effect of exosomal markers on overall survival of patients with pancreatic cancer.](WJCC-7-171-g010){#F10}

![Forest plot evaluating the effect of exosomal markers on overall survival of patients with liver cancer.](WJCC-7-171-g011){#F11}

![Forest plot evaluating the effect of exosomal markers on overall survival of patients with lung cancer.](WJCC-7-171-g012){#F12}

DISCUSSION
==========

Exosomes play important roles in cancer development *via* intercellular communication, promoting cell metastasis and developing drug resistance\[[@B19]-[@B21]\]. Importantly, exosomes are frequently secreted by the cancers and are widely distributed in many body fluids. Therefore, they can be detected in blood, saliva and urine. Exosomal biomarkers have better performance in cancer diagnosis and prognosis than liquid biopsy used alone\[[@B24]-[@B26]\]. However, the methods of isolating exosomes from liquid biopsy varies between studies. Ultracentrifugation or the use of commercial isolation kits are common methods in extracting exosomes. Ultracentrifugation gives highly pure exosomes but the isolation efficiency is relatively low; whereas, the use of commercial kits maximizes the efficiency with the loss of purity\[[@B95],[@B96]\]. Therefore, a standardized protocol of detecting exosomal biomarkers is greatly needed.

There are some limitations of our meta-analysis. We excluded studies that utilized combined biomarkers because this cannot tell the performance of individual biomarkers\[[@B97],[@B98]\]. For example, a six-microRNA panel was developed for diagnosis of lung cancer but miR-409-3p, miR-425-5p and miR-584-5p were not significantly dysregulated in patients' exosomes\[[@B98]\]. This may reduce the diagnostic performance of other biomarkers in the same panel. Since many of the individual biomarkers in the panel were significantly differentially expressed in cancer exosomes, further studies may be needed to explore the correlation of these potential biomarkers with patients' characteristics and their performances in cancer diagnosis and prognosis.

A further limitation is that we focused on exosomal markers only in cancer diagnosis and prognosis and excluded tissue-based biomarkers from this meta-analysis. In fact, many studies have reported that expression levels in exosomes and in tissues are highly associated\[[@B35],[@B66]\]. This suggests that many exosomal markers can reflect the situation in cancer cells, and this notion has been developed for potential biomarkers in various cancers. Importantly, this strong association may also suggest that many tissue-based biomarkers can be developed into non-invasive exosomal biomarkers in cancer diagnosis.

Notably, most of the included studies are retrospective, having been performed on stored samples. However, the main disadvantage of the retrospective study is its lack of complete clinicpathological information\[[@B30]\], which lowers the quality of study. Despite the above limitations, our meta-analysis indicates that exosomes can be potential biomarkers in cancer diagnosis and prognosis. Further large prospective studies are greatly needed to clarify the performance of exosomal biomarkers in cancer diagnosis and prognosis.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Exosomes, which are widely distributed in body fluids, including blood, bile, urine and saliva, are microvesicles of 30-100 nm diameter in size. Cancer-derived exosomes carry a wide variety of DNA, RNA, proteins and lipids, and may serve as novel biomarkers in cancer.

Research motivation
-------------------

Exosomes may function as exosomal biomarkers in cancer diagnosis and prognosis.

Research objectives
-------------------

To summarize the performance of exosomal biomarkers in cancer diagnosis and prognosis.

Research methods
----------------

Relevant studies in the literature were identified using the PubMed database. QUADAS-2 and REMARK were used to assess the quality of the included studies. For diagnostic biomarkers, 47 biomarkers and 2240 patients from 30 studies were included.

Research results
----------------

These exosomal biomarkers had excellent diagnostic ability in various types of cancer, with good sensitivity and specificity. A total of 50 biomarkers and 4797 patients from 42 studies were included for the prognostic markers. We observed that exosomal biomarkers had prognostic values in overall survival, disease-free survival and recurrence-free survival.

Research conclusions
--------------------

Exosomes could be potential biomarkers in cancer diagnosis and prognosis.

Research perspectives
---------------------

Further large prospective studies are needed to clarity the performance of exosomal biomarkers in cancer diagnosis and prognosis, through exosomes can be potential biomarkers in cancer diagnosis and prognosis.
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